金斯瑞生物科技联营公司公布CARVYKTI研究数据

财中社
Dec 07

  12月7日,金斯瑞生物科技(01548)发布公告,宣布其联营公司传奇生物科技股份有限公司于2025年12月6日(纽约时间)在美国血液学会年会上发布了CARVYKTI®在复发或难治性多发性骨髓瘤患者中的临床及转化研究数据。

  公告中提到,传奇在该年会上展示了CARTITUDE-1和CARTITUDE-4研究的长期随访数据,以及CARTITUDE-4的最新III期研究结果。此外,传奇还展示了双靶点同种异体CAR-T候选产品LUCAR-G39D的首次人体试验数据。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10